Back to results
US 12,421,281 B2Granted
Cyclosporine compositions and methods of use
AssigneeBacainn Biotherapeutics, Ltd.
InventorsChris Murphy, Ronald Farquhar, Roland E. Dolle
Life of this patent
Estimating the term…
Abstract
Disclosed herein are cyclosporine compounds and methods for use in the treatment or prevention of neutrophil-mediated inflammation, wherein the compounds inhibit the activity of MRP2 and FPRL.
Claims18
A compound having the structure of Formula I,
- a stereoisomer thereof, or a pharmaceutically acceptable salt of the foregoing,
- wherein
- L1 is a C1-6 alkylene group optionally substituted with one or more F;
- L2 is absent or is a linker selected from O, NH, or a C1-12 alkylene or heteroalkylene group;
- L3 is a C1-6 alkylene group;
- L4 is a methylene or ethylene group;
- and
- R is a polyethylene glycol (PEG) group.
5 more elements
A method for treating a disease associated with neutrophil-mediated inflammation in a target tissue of a mammalian subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of formula I:
- a stereoisomer thereof, or a pharmaceutically acceptable salt of the foregoing, wherein
- L1 is a C1-6 alkylene group optionally substituted with one or more F;
- L2 is absent or is a linker selected from O, NH, or a C1-12 alkylene or heteroalkylene group;
- L3 is a C1-6 alkylene group;
- L4 is a methylene or ethylene group;
- and
- R is a polyethylene glycol (PEG) group,
- wherein the disease is:
- an intestinal disease selected from the group consisting of Crohn's disease, celiac disease, ulcerative colitis, infectious/non-infectious enterocolitis, and inflammatory bowel disease (IBD);
- an inflammatory skin disease selected from the group consisting of dermatitis, rosacea, seborrheic dermatitis, and psoriasis;
- or
- an ocular disease selected from the group consisting of uveitis, retinitis, keratitis, and macular degeneration.
9 more elements
Dependencies are inferred from the claim text.